TCRT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TCRT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alaunos Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-3.36 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-28.49 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. Alaunos Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-3.36 Mil. Alaunos Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Alaunos Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -336,000.00%.
Alaunos Therapeutics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alaunos Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -375.10%. Alaunos Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -920.54%.
The historical data trend for Alaunos Therapeutics's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alaunos Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Operating Income | Get a 7-Day Free Trial | -57.86 | -80.36 | -76.81 | -35.24 | -28.49 |
Alaunos Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Operating Income | Get a 7-Day Free Trial | -8.52 | -9.67 | -8.23 | -7.23 | -3.36 |
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alaunos Therapeutics (NAS:TCRT) Operating Income Explanation
1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Alaunos Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:
ROC % (Q: Dec. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2023 ) | + | Invested Capital (Q: Dec. 2023 )) | / count ) |
= | -13.44 * ( 1 - 0% ) | / | ( (6.878 | + | 0.288) | / 2 ) |
= | -13.44 | / | 3.583 | |||
= | -375.10 % |
where
Invested Capital | (Q: Sep. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 19.44 | - | 4.369 | - | ( 11.944 | - | max(0, 4.676 | - | 12.869 | + | 11.944 | )) |
= | 6.878 |
Invested Capital | (Q: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 8.263 | - | 1.913 | - | ( 6.062 | - | max(0, 1.956 | - | 8.261 | + | 6.062 | )) |
= | 0.288 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.
2. Joel Greenblatt's definition of Return on Capital:
Alaunos Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:
ROC (Joel Greenblatt) % | (Q: Dec. 2023 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Sep. 2023 | Q: Dec. 2023 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -31.372 | / | ( ( (6.571 + max(-3.444, 0)) | + | (0.002 + max(0.243, 0)) ) | / | 2 ) |
= | -31.372 | / | ( ( 6.571 | + | 0.245 ) | / | 2 ) |
= | -31.372 | / | 3.408 | ||||
= | -920.54 % |
where Working Capital is:
Working Capital | (Q: Sep. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0 | + | 0 | + | 0.925) | - | (4.369 | + | 0 | + | 0) |
= | -3.444 |
Working Capital | (Q: Dec. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0.001 | + | 0 | + | 2.198) | - | (1.913 | + | 0 | + | 0.043) |
= | 0.243 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
3. Operating Income is also linked to Operating Margin %:
Alaunos Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
Operating Margin % | = | Operating Income (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | -3.36 | / | 0.001 | |
= | -336,000.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of Alaunos Therapeutics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Boyle Kevin S. Sr. | director, officer: Chief Executive Officer | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
Robert Hofmeister | director | C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142 |
Jaime Vieser | director | ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129 |
Robert W Postma | director | 141 MECOX ROAD, WATER MILL NY 11976 |
Michael Wong | officer: VP, Finance | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129 |
Abhishek K Srivastava | officer: See Remarks | C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054 |
Holger Weis | director | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
Christopher Bowden | director | 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139 |
Mary Thistle | director | C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
James Huang | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Drew Deniger | officer: VP, Research & Development | C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054 |
Groot Eleanor De | officer: EVP, Operations | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
Melinda Lackey | officer: Senior Vice President, Legal | C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054 |
Heidi Hagen | director | AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105 |
Raffaele Baffa | officer: Chief Medical Officer | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
From GuruFocus
By sperokesalga sperokesalga • 03-30-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 11-14-2022
By PurpleRose PurpleRose • 08-15-2022
By sperokesalga sperokesalga • 05-03-2023
By GlobeNewswire GlobeNewswire • 03-29-2023
By GuruFocusNews GuruFocusNews • 06-25-2022
By Marketwired • 08-14-2023
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 05-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.